Baseline predictors of response to TNF-α blocking therapy in ankylosing spondylitis

Current Opinion in Rheumatology

Volumn 24, Issue 3, 2012, Pages 290-298

  Arends, Suzanne ^a,b   Van Der Veer, Eveline ^a   Kallenberg, Cees G M ^a   Brouwer, Elisabeth ^a   Spoorenberg, Anneke ^a,b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b MEDICAL CENTER LEEUWARDEN   (Netherlands)

Author keywords

ankylosing spondylitis; biomarkers; predictors; TNF a blocking therapy; treatment response

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; ETANERCEPT; GOLIMUMAB; HLA B27 ANTIGEN; IMMUNOGLOBULIN M; INFLIXIMAB; INTERLEUKIN 1ALPHA; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; SALAZOSULFAPYRIDINE; SERUM AMYLOID A; STROMELYSIN; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VASCULOTROPIN;

AGE; ANGIOGENESIS; ANKYLOSING SPONDYLITIS; BACKACHE; CLINICAL PRACTICE; DISEASE ACTIVITY; DISEASE DURATION; DRUG COST; DRUG EFFICACY; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; FUNCTIONAL STATUS; HUMAN; JOINT DESTRUCTION; MORNING STIFFNESS; MYALGIA; PHYSIOTHERAPY; PREDICTOR VARIABLE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEX; SPINE MOBILITY; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VISUAL ANALOG SCALE;

ANTIRHEUMATIC AGENTS; BIOLOGICAL MARKERS; FEMALE; HUMANS; MALE; PROGNOSIS; SEVERITY OF ILLNESS INDEX; SEX FACTORS; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84859269583     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0b013e32835257c5     Document Type: Review

References (41)

1. Braun J, Deodhar A, Dijkmans B, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period. Arthritis Rheum 2008; 59:1270-1278
2. Dijkmans B, Emery P, Hakala M, et al. Etanercept in the long term treatment of patients with ankylosing spondylitis. J Rheumatol 2009; 36:1256-1264
3. Van der Heijde D, Schiff MH, Sieper J, et al. Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. Ann Rheum Dis 2009; 68:922-929
4. Braun J, Deodhar A, Inman RD, et al. Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study. Ann Rheum Dis 2011. doi: 10.1136/ard.2011.154799. [Epub ahead of print]
5. Van der Heijde D, Sieper J, Maksymowych WP, et al. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis 2011; 70:905-908
6. Rudwaleit M, Khan MA, Sieper J. The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria? Arthritis Rheum 2005; 52:1000-1008 (Pubitemid 40530105)
7. Baraliakos X, Listing J, Rudwaleit M, et al. Progression of radiographic damage in patients with ankylosing spondylitis: defining the central role of syndesmophytes. Ann Rheum Dis 2007; 66:910-915 (Pubitemid 46999792)
8. Geusens P, Vosse D, van der Linden S. Osteoporosis and vertebral fractures in ankylosing spondylitis. Curr Opin Rheumatol 2007; 19:335-339 (Pubitemid 46884187)
9. Vosse D, Landewe R, van der Heijde D, et al. Ankylosing spondylitis and the risk of fracture: results from a large primary care-based nested case-control study. Ann Rheum Dis 2009; 68:1839-1842
10. Arends S, Spoorenberg A, Bruyn GA, et al. The relation between bone mineral density, bone turnover markers, and vitamin D status in ankylosing spondylitis patients with active disease: a cross-sectional analysis. Osteoporos Int 2011; 22:1431-1439
11. Braun J, Sieper J. Ankylosing spondylitis. Lancet 2007; 369:1379-1390 (Pubitemid 46590387)
12. Braun J, van den Berg R, Baraliakos X, et al. 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011; 70:896-904
13. Van der Heijde D, Kivitz A, Schiff MH, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006; 54:2136-2146 (Pubitemid 44051069)
14. Inman RD, Davis JC Jr, van der Heijde D, et al. Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 2008; 58:3402-3412
15. Rudwaleit M, Listing J, Brandt J, et al. Prediction of a major clinical response [BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. Ann Rheum Dis 2004; 63:665-670 (Pubitemid 38658395)
16. Sieper J, Rudwaleit M, Baraliakos X, et al. The Assessment of Spondylo-Arthritis international Society [ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis 2009; 68 (Suppl. 2):ii1-ii44
17. Anderson JJ, Baron G, van der Heijde D, et al. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001; 44:1876-1886 (Pubitemid 32758236)
18. Van der Heijde D, Dijkmans B, Geusens P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005; 52:582-591 (Pubitemid 40216323)
19. Davis JC Jr, van der Heijde D, Braun J, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 2003; 48:3230-3236 (Pubitemid 37409337)
20. De Vries MK, van Eijk IC, van der Horst-Bruinsma IE, et al. Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid A protein for patient selection and monitoring of antitumor necrosis factor treatment in ankylosing spondylitis. Arthritis Rheum 2009; 61:1484-1490
21. Pedersen SJ, Sorensen IJ, Hermann KG, et al. Responsiveness of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and clinical and MRI measures of disease activity in a 1-year follow-up study of patients with axial spondyloarthritis treated with tumour necrosis factor alpha inhibitors. Ann Rheum Dis 2010; 69:1065-1071.
22. Arends S, Brouwer E, van der Veer E, et al. Baseline predictors of response and discontinuation of TNF-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study. Arthritis Res Ther 2011; 13:R94.
23. Lord PA, Farragher TM, Lunt M, et al. Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2010; 49:563-570.
24. Glintborg B, Ostergaard M, Krogh NS, et al. Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with antitumour necrosis factor: results from 8 years' surveillance in the Danish nationwide DANBIO registry. Ann Rheum Dis 2010; 69:2002-2008.
25. Pavelka K, Forejtova S, Stolfa J, et al. Anti-TNF therapy of ankylosing spondylitis in clinical practice: results from the Czech national registry ATTRA. Clin Exp Rheumatol 2009; 27:958-963
26. Kristensen LE, Karlsson JA, Englund M, et al. Presence of peripheral arthritis and male sex predicting continuation of antitumor necrosis factor therapy in ankylosing spondylitis: an observational prospective cohort study from the South Swedish Arthritis Treatment Group Register. Arthritis Care Res (Hoboken) 2010; 62:1362-1369.
27. Schabert VF, Goodman S, Watson C, et al. Annual costs of tumor necrosis factor inhibitors using real-world data in a commercially insured population in the United States. J Med Econ 2011. doi: 10.3111/13696998.2011.644645. [Epub ahead of print]
28. Gerard-Benoist S, Leux C, Le Goff B, et al. Frequency of hospitalization and severe events in 497 spondylarthritis patients treated with anti-TNF drugs: comparisons with 423 RA patients. Joint Bone Spine 2011. doi: 10.1016/j.jbspin.2011.09.010. [Epub ahead of print]
29. Davis JC Jr, van der Heijde DM, Dougados M, et al. Baseline factors that influence ASAS 20 response in patients with ankylosing spondylitis treated with etanercept. J Rheumatol 2005; 32:1751-1754 (Pubitemid 41324816)
30. Rudwaleit M, Schwarzlose S, Hilgert ES, et al. MRI in predicting a major clinical response to antitumour necrosis factor treatment in ankylosing spondylitis. Ann Rheum Dis 2008; 67:1276-1281
31. Vastesaeger N, van der Heijde D, Inman RD, et al. Predicting the outcome of ankylosing spondylitis therapy. Ann Rheum Dis 2011; 70: 973-981.
32. Wagner C, Visvanathan S, Braun J, et al. Serum markers associated with clinical improvement in patients with ankylosing spondylitis treated with golimumab. Ann Rheum Dis 2011. doi: 10.1136/ard.2010.148890. [Epub ahead of print]
33. Rudwaleit M, Claudepierre P, Wordsworth P, et al. Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis. J Rheumatol 2009; 36:801-808
34. Luc M, Gossec L, Ruyssen-Witrand A, et al. C-reactive protein predicts tumor necrosis factor-alpha blocker retention rate in axial ankylosing spondylitis. J Rheumatol 2007; 34:2078-2081 (Pubitemid 47548214)
35. Pedersen SJ, Sorensen IJ, Garnero P, et al. ASDAS, BASDAI and different treatment responses and their relation to biomarkers of inflammation, cartilage and bone turnover in patients with axial spondyloarthritis treated with TNF{alpha} inhibitors. Ann Rheum Dis 2011; 70:1375-1381
36. Visvanathan S, Wagner C, Marini JC, et al. Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab. Ann Rheum Dis 2008; 67:511-517 (Pubitemid 351498433)
37. Lukas C, Landewe R, Sieper J, et al. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. Ann Rheum Dis 2009; 68:18-24
38. Van der Heijde D, Lie E, Kvien TK, et al. ASDAS, a highly discriminatory ASASendorsed disease activity score in patients with ankylosing spondylitis. Ann Rheum Dis 2009; 68:1811-1818
39. Romero-Sanchez C, Robinson WH, Tomooka BH, et al. Identification of acute phase reactants and cytokines useful for monitoring infliximab therapy in ankylosing spondylitis. Clin Rheumatol 2008; 27:1429-1435
40. Woo JH, Lee HJ, Sung IH, Kim TH. Changes of clinical response and bone biochemical markers in patients with ankylosing spondylitis taking etanercept. J Rheumatol 2007; 34:1753-1759
41. Arends S, van der Veer E, Groen H, et al. Serum MMP-3 level as a biomarker for monitoring and predicting response to etanercept treatment in ankylosing spondylitis. J Rheumatol 2011; 38:1644-1650.